Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of Nuvastatic 300 capsule on reducing fatigue related to cancer treatment in adults with metastatic colon cancer who are undergoing first-line chemotherapy. The main goals are to determine if Nuvastatic 300 capsule can significantly reduce cancer-related fatigue compared to a placebo and to assess its safety and tolerability in this patient group. This is a phase III randomized, double-blind, placebo-controlled study sponsored by Natureceuticals Sdn Bhd. Participants will receive either Nuvastatic 300 capsules or placebo capsules, taken three times daily for six cycles lasting about 20 days each, totaling approximately 120 treatment days. All participants will continue their standard chemotherapy during the trial. Blood samples will be collected at screening and at the end of treatment to monitor health and treatment effects. During the study, participants will complete diaries and fatigue assessments according to the protocol. Researchers will measure reduction in cancer-related fatigue from screening to the end of treatment, as well as overall quality of life and functional improvements. The trial includes safety monitoring and will last about six months from screening through treatment completion.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of darolutamide alongside standard androgen deprivation therapy ADT in Indian men with high-risk non-metastatic castration-resistant prostate cancer nmCRPC. This type of prostate cancer continues to progress despite very low testosterone levels. The study aims to collect detailed safety data and compare it with previous research involving darolutamide, which did not include Indian participants. Participants will take darolutamide tablets orally twice daily along with their ongoing ADT. They will have visits every 16 weeks from the start until their cancer worsens, they develop medical issues, leave the study, or the study ends. During these visits, various tests and assessments will be performed, including blood and urine sampling, physical exams, heart activity monitoring with ECG, and evaluation of daily living abilities using the ECOG performance status. Throughout the study, researchers will monitor adverse events, lab abnormalities, vital signs, and changes in participants health status up to approximately 15 months. They will also assess changes in prostate-specific antigen PSA levels and track the time to additional cancer treatments. Participants may continue darolutamide after the trial if they benefit from it. The total study duration extends up to the primary completion date in April 2027.
Actively Recruiting
Researchers are evaluating whether Nuvastatic 300 mg capsules can reduce cancer-related fatigue in adult female patients with triple-negative metastatic breast cancer who are undergoing first-line chemotherapy. This phase III trial compares Nuvastatic 300 mg capsules to a placebo to assess their effects on fatigue levels and to evaluate the safety and tolerability of Nuvastatic in this patient group. Participants will receive either Nuvastatic 300 mg capsules or placebo capsules, taken three times daily for three cycles lasting 20 days each, totaling approximately 60 days of treatment. They will continue their standard chemotherapy throughout the study. Blood samples will be collected at screening and at the end of treatment to monitor participants health and treatment effects. During the study, participants will complete fatigue assessments and patient diaries following the study protocol. Researchers will measure the reduction in cancer-related fatigue from screening to the end of treatment, about six months. Secondary measures include overall quality of life and functional improvements. The study also includes safety monitoring and follow-up during the entire study period.